Lutetium-177-PSMA therapy for recurrent/metastatic salivary gland cancer: a prospective pilot study

van Ruitenbeek, N.J.

Uijen, M.J.M.

Driessen, C.M.L.

Peters, S.M.B.

Privé, B.M.

van Engen-van Grunsven, A.C.H.

Konijnenberg, M.

Gotthardt, M.

Nagarajah, J.

Van Herpen, C.M.L.

The data was created in the context of a phase II clinical study at Radboudumc, - the LUPSA trial - investigating the feasibility, safety, and efficacy of lutetium-177-PSMA therapy for patients with recurrent and/or metastatic salivary gland cancer. This study was initiated after previous studies demonstrating relevant uptake of gallium-68-PSMA-11 on PET/CT in adenoid cystic carcinoma and salivary duct carcinoma, two subtypes of salivary gland cancer. In PSMA-positive prostate cancer, lutetium-177-PSMA therapy is an effective treatment strategy. Therefore, this prospective pilot study investigated the safety, feasibility, efficacy and radiation dosimetry of 177-lutatium--PSMA-I&T treatment in patients with adenoid cystic carcinoma and salivary duct carcinoma. This collection contains data about progression-free survival and overall survival (folder 'survival'), toxicity (folder 'Toxicity'), and dosimetry (folders 'Dosimetry_bone_marrow', 'Dosimetry_kidneys', 'Dosimetry_salivary_glands', 'Dosimetry_tumors')